


Policy Statement	Treatments for Erectile Dysfunction
Policy No:	PCN 368-2018 (replaces PCN 164-2015)
Date of Issue	September 2018
Review Date:	September 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The PCN supports the treatment of erectile dysfunction in line with the pathway published on the Prescribing Advisory Database and embedded below for information</p> <p> Erectile Dysfunction Pathway in Primary C</p>	
<p>Key Considerations:</p> <p>Consider phosphodiesterase type-5 (PDE-5) inhibitors (if there are no contraindications):</p> <p>For patients who meet SLS criteria</p> <ul style="list-style-type: none"> ○ Sildenafil (generic): It is reasonable to prescribe up to 3 tablets per week OR ○ Tadalafil (generic) It is reasonable to prescribe up to 1 tablet per week as longer acting than sildenafil <ul style="list-style-type: none"> ▪ Sildenafil or Tadalafil are considered as GREEN on the traffic light system <p>For patients who do NOT meet SLS criteria</p> <ul style="list-style-type: none"> ● Generic sildenafil is currently approved for prescribing for those patients <ul style="list-style-type: none"> ▪ Sildenafil is considered as GREEN on the traffic light system <p>Tadalafil (Cialis) - ONCE DAILY Considered BLACK on the traffic light system see policy statement and supporting information from January 2018 on the PAD.</p> <ul style="list-style-type: none"> ● http://pad.res360.net/Content/Documents/PCN%20313-2018%20Once%20daily%20tadalafil%20Policy%20Statement.pdf <p>Vardenafil, avanafil & Viagra® There was no place in therapy recommended for vardenafil, avanafil or Viagra®.</p> <ul style="list-style-type: none"> ▪ These three drugs are considered BLACK on the traffic light system 	

Alprostadil

These continue to be restricted by SLS criteria as identified in the Health Service Circular (HSC) 1999/148 at a maximum frequency of dosing of **four** times per month.

- **Alprostadil cream (Vitaros®)** is now available as a treatment option in primary care for patients who do not respond to PDE-5 inhibitors.
 - This can be initiated in primary care and is considered **GREEN** on the traffic light system
- **Alprostadil intracavernosal injections and intra-urethral applications (Muse®)** may be more effective than the alprostadil cream.
 - It should be initiated in secondary care, patients trained to self-administer and treatment shown to be effective before discharge for GPs to prescribe.
 - This is considered to be **BLUE (no information sheet)** on the traffic light system and any information on prescribing is available through www.medicines.org

Vacuum pumps

- Vacuum pumps are now approved for prescribing in primary care. They are most useful in patients with nerve damage, whether by surgery or for medical reasons.
- The brand has not been specified but must be selected from the options available in the drug tariff and the prescriber must be able to provide appropriate training.
- Training is available from some of the agents marketing these products but GPs must have patient consent before transferring any details.
 - This can be initiated in primary care and is considered **GREEN** on the traffic light system

Date taken to Prescribing Clinical Network	5 th September 2018
Agreed by PCN members	18 th September 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG